(MedPage Today) — Maintenance therapy with continuous lenalidomide (Revlimid) did not significantly improve overall survival (OS) in patients with standard-risk, newly diagnosed multiple myeloma, the phase III ENDURANCE trial showed. Among patients…
Source: MedPage Today — Headlines
